Obesity and cancer risk: evidence, mechanisms, and recommendations

Abstract

Obesity, a growing health problem worldwide, has been associated with the metabolic syndrome, diabetes, cardiovascular disease, hypertension, and other chronic diseases. Recently, the obesity–cancer link has received much attention. Epidemiological studies have shown that obesity is also associated with increased risk of several cancer types, including colon, breast, endometrium, liver, kidney, esophagus, gastric, pancreatic, gallbladder, and leukemia, and can also lead to poorer treatment and increased cancer‐related mortality. Biological mechanisms underlying the relationship between obesity and cancer are not well understood. They include modulation of energy balance and calorie restriction, growth factors, multiple signaling pathways, and inflammatory processes. Key among the signaling pathways linking obesity and cancer is the PI3K/Akt/mTOR cascade, which is a target of many of the obesity‐associated factors and regulates cell proliferation and survival. Understanding the molecular and cellular mechanisms of the obesity–cancer connection is important in developing potential therapeutics. The link between obesity and cancer underscores the recommendation to maintain a healthy body weight throughout life as one of the most important ways to protect against cancer.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 61

1. 1.

   Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. 2007.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   Karnik SD, Kanekar A. Childhood obesity: a global public health crisis. Int. J. Prev. Med. 2012;3:1-3.

   Not in our library

4. 4.

   Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. J. Am. Med. Assoc. 2012;307:491-497.

   Not in our library10.1001/jama.2012.39

5. 5.

   Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. J. Am. Med. Assoc. 2012;307:483-490.

   Not in our library10.1001/jama.2012.40

6. 6.

   Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J. Clin. 2011;61:69-90.

   Not in our library10.3322/caac.20107

7. 7.

   Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62:10-29.

   Not in our library10.3322/caac.20138

8. 8.

   Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008. 2010.

   Not in our library

9. 9.

   Rossen LM, Rossen EA. Obesity 101. 2012.

   Not in our library

10. 10.

    Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 2010;363:2211-2219.

    Not in our library10.1056/nejmoa1000367

11. 11.

    Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083-1101.

    Not in our library10.1634/theoncologist.2010-0206

12. 12.

    Kaidar-Person O, Bar-Sela G, Person B. The two major epidemics of the twenty-first century: obesity and cancer. Obes. Surg. 2011;21:1792-1797.

    Not in our library10.1007/s11695-011-0490-2

13. 13.

    Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu. Rev. Nutr. 2012;32:311-342.

    Not in our library10.1146/annurev-nutr-071811-150713

14. 14.

    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003;348:1625-1638.

    Not in our library10.1056/nejmoa021423

15. 15.

    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and mechanisms. Nat. Rev. Cancer. 2004;4:579-591.

    Not in our library10.1038/nrc1408

16. 16.

    Drew JE. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc. Nutr. Soc. 2012;71:175-180.

    Not in our library10.1017/s0029665111003259

17. 17.

    Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 2012;33:547-594.

    Not in our library10.1210/er.2011-1015

18. 18.

    Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology. 2011;152:2546-2551.

    Not in our library10.1210/en.2011-0231

19. 19.

    Hursting SD, Berger NA. Energy balance, host-related factors, and cancer. J. Clin. Oncology. 2010;28:4058-4065.

    Not in our library10.1200/jco.2010.27.9935

20. 20.

    Chen J. Multiple signal pathways in obesity-associated cancer. Obes. Rev. 2011;12:1063-1070.

    Not in our library10.1111/j.1467-789x.2011.00917.x

21. 21.

    Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann. N.Y. Acad. Sci. 2011;1229:45-52.

    Not in our library10.1111/j.1749-6632.2011.06096.x

22. 22.

    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004;89:2548-2556.

    Not in our library10.1210/jc.2004-0395

23. 23.

    Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;100:389-395.

    Not in our library10.1111/j.1349-7006.2008.01053.x

24. 24.

    Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int. J. Cancer. 2008;123:2543-2556.

    Not in our library10.1002/ijc.23821

25. 25.

    Hursting SD, Lashinger LM, Wheatley KW, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best. Pract. Res. Endocrinol. Metab. 2008;22:659-669.

    Not in our library10.1016/j.beem.2008.08.009

26. 26.

    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 2002;11:1531-1543.

    Not in our library

27. 27.

    Taubes R. Cancer research. Unraveling the obesity-cancer connection. Science. 2012;335:28.

    Not in our library10.1126/science.335.6064.28

28. 28.

    Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 2012;48:R31-R43.

    Not in our library10.1530/jme-12-0007

29. 29.

    Hursting SD, Smith SM, Lashinger LM, et al. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis. 2010;31:83-89.

    Not in our library10.1093/carcin/bgp280

30. 30.

    Zhu Z, Jiang W, McGinley J, et al. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. Mol. Carcinog. 2005;42:170-176.

    Not in our library10.1002/mc.20071

31. 31.

    Hursting SD, Switzer BR, French JE, Kari FW. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fisher rats. Cancer Res. 1993;53:2750-2757.

    Not in our library

32. 32.

    Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997;57:4667-4672.

    Not in our library

33. 33.

    Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol. Metab. 2006;17:328-336.

    Not in our library10.1016/j.tem.2006.08.006

34. 34.

    Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009;8:627-644.

    Not in our library10.1038/nrd2926

35. 35.

    Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458:725-731.

    Not in our library10.1038/nature07782

36. 36.

    Moore T, Beltran L, Carbajal S, et al. Dietary energy balance modulates signaling through the Akt/Mammalian Target of Rapamycin pathways in multiple epithelial tissues. Cancer Prev. Res. 2008;1:65-76.

    Not in our library10.1158/1940-6207.capr-08-0022

37. 37.

    Woods SC, Seeley RJ, Porte D, et al. Signals that regulate food intake and energy homeostasis. Science. 1998;280:1378-1383.

    Not in our library10.1126/science.280.5368.1378

38. 38.

    Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 2008;13:252-259.

    Not in our library10.1016/j.molmed.2007.04.002

39. 39.

    Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of Akt and mTOR in mammary carcinomas, mammary gland, and liver. Cancer Res. 2008;68:5492-5499.

    Not in our library10.1158/0008-5472.can-07-6721

40. 40.

    Fierz Y, Novosyadlyy R, Vijayakumar A, et al. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr. Relat. Cancer. 2010;17:941-951.

    Not in our library10.1677/erc-10-0091

41. 41.

    Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70:741-751.

    Not in our library10.1158/0008-5472.can-09-2141

42. 42.

    Moore T, Carbajal S, Beltran L, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I level. Cancer Res. 2008;68:3680-3688.

    Not in our library10.1158/0008-5472.can-07-6271

43. 43.

    Olivo-Marston SE, Hursting SD, Lavigne J, et al. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol. Carcinog. 2009;48:1071-1076.

    Not in our library10.1002/mc.20577

44. 44.

    Chakraborty A, Kim S, Snyder SH. Inositol pyrophosphates as mammalian cell signals. Sci. Signal. 2011;4:188.

    Not in our library10.1126/scisignal.2001958

45. 45.

    Chakraborty A, Koldobskiy MA, Bello NT, et al. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell. 2010;143:897-910.

    Not in our library10.1016/j.cell.2010.11.032

46. 46.

    Shames DS, Mina JD. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc. Natl. Acad. Sci. U. S. A. 2008;105:1389-1390.

    Not in our library10.1073/pnas.0711993105

47. 47.

    Aoki M, Sobek V, Maslyar DJ, et al. Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene. 2002;10:6983-6991.

    Not in our library10.1038/sj.onc.1205796

48. 48.

    Chakraborty A, Koldobskiy MA, Sixt KM, et al. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 2008;105:1134-1139.

    Not in our library10.1073/pnas.0711168105

49. 49.

    Koldobskiy MA, Chakraborty A, Werner JK, et al. p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 2010;107:20947-20951.

    Not in our library10.1073/pnas.1015671107

50. 50.

    Chakraborty A, Werner JK, Koldobskiy MA, et al. Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 2011;108:2205-2209.

    Not in our library10.1073/pnas.1019381108

51. 51.

    Morrison BH, Haney R, Lamarre E, et al. Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. Oncogene. 2009;28:2383-2392.

    Not in our library10.1038/onc.2009.113

52. 52.

    Morrison BH, Bauer JA, Hu J, et al. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma celle to multiple cancer therapeutics. Oncogene. 2002;21:1882-1889.

    Not in our library10.1038/sj/onc/1205265

53. 53.

    Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-β in ovarian carcinoma. J. Biol. Chem. 2001;276:24965-24970.

    Not in our library10.1074/jbc.m101161200

54. 54.

    Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci. Transl. Med. 2012;4:127.

    Not in our library10.1126/scitranslmed.3003218

55. 55.

    Doll R, Peto R. The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in United States Today. 1981.

    Not in our library

56. 56.

    Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc. Nutr. Soc. 2008;67:253-256.

    Not in our library10.1017/s002966510800712x

57. 57.

    Thompson R. Preventing cancer: the role of food, nutrition, and physical activity. J. Fam. Health Care. 2010;20:100-102.

    Not in our library

58. 58.

    Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch. Intern. Med. 2005;165:1267-1273.

    Not in our library10.1001/archinte.165.11.1267

59. 59.

    Wong JR, Gao Z, Merrick S, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int. J. Radiat. Oncol. Biol. Phys. 2009;75:49-55.

    Not in our library10.1016/j.ijrobp.2008.07.049

60. 60.

    Healy LA, Ryan AM, Sutton E, et al. Impact of obesity on surgical and oncologic outcomes in the management of colorectal cancer. Int. J. Colorectal Dis. 2010;25:1293-1299.

    Not in our library10.1007/s00384-010-0963-0

61. 61.

    Al-Refaie WB, Parsons HM, Henderson WG, et al. Body mass index and major cancer surgery outcomes: lack of association or need for alternative measurements of obesity. Ann. Surg. Oncol. 2010;17:2264-2273.

    Not in our library10.1245/s10434-010-1023-2

Cited by papers we hold 10

• Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment · 2023
  No notice
• Role of Inositols and Inositol Phosphates in Energy Metabolism · 2020
  No notice
• FTO – A Common Genetic Basis for Obesity and Cancer · 2020
  No notice
• Nutrients and Oxidative Stress: Friend or Foe? · 2018
  No notice
• Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review · 2017
  No notice
• Sex, Body Mass Index, and Dietary Fiber Intake Influence the Human Gut Microbiome · 2015
  No notice
• Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults · 2014
  No notice
• Nutritionally Mediated Oxidative Stress and Inflammation · 2013
  No notice
• Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State · 2013
  No notice
• Diabetes and cancer: two diseases with obesity as a common risk factor · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.